SCHEMBL13627900

SCHEMBL13627900

O=C1/C(=N\O)c2cc(Br)ccc2N1Cc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.69
ALDH3A1 P30838 8/20 0.69
ALDH2 P05091 6/20 0.69
CA1 P00915 2/20 0.59
CA2 P00918 2/20 0.59
CA4 P22748 1/20 0.59
CA7 P43166 1/20 0.59
ACHE P22303 2/20 0.57
CA12 O43570 1/20 0.55
CA9 Q16790 1/20 0.55
UCHL1 P09936 2/20 0.53
UCHL3 P15374 2/20 0.53
CHRM1 P11229 2/20 0.50
CHRM5 P08912 1/20 0.50
CHRM3 P20309 1/20 0.50
MAPT P10636 2/20 0.48
TSHR P16473 2/20 0.48
LRRK2 Q5S007 1/20 0.48
PKM P14618 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627901 0.87 ACHE (0.58) ALDH1A1ALDH3A1ALDH2CA1CA2
SCHEMBL13627905 0.87 ACHE (0.60) ALDH1A1ALDH3A1ALDH2CA1CA2
SCHEMBL13627906 0.87 ALDH1A1 (0.52) ALDH1A1ALDH3A1ALDH2CA1CA2
SCHEMBL13627908 0.87 CA1 (0.58) ALDH1A1ALDH3A1ALDH2CA1CA2
SCHEMBL13627927 0.85 ALDH3A1 (0.68) ALDH1A1ALDH3A1ALDH2CA1CA2
SCHEMBL13627917 0.84 ACHE (0.52) ALDH1A1ALDH3A1ALDH2CA1CA2
SCHEMBL13627936 0.84 TRPA1 (0.62) ALDH1A1ALDH3A1ALDH2CHRM1CHRM5
SCHEMBL7611054 0.83 ALDH1A1 (0.66) ALDH1A1ALDH3A1ALDH2CA1CA2
SCHEMBL7611051 0.83 ALDH1A1 (0.66) ALDH1A1ALDH3A1ALDH2CA1CA2
SCHEMBL13627904 0.83 ACHE (0.53) ALDH1A1ALDH3A1ALDH2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ALDH1A1 4310/4885ALDH3A1 4247/4885ALDH2 3451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.